and everyone. good Jim, you, Thank afternoon,
especially Before diabetes of driving first just I the people financial is of pipeline. confident in management company. am financial to lives the I transforming our started, quarter thousands say into performance. we're part strong how I I that of results, developments of be improving getting am while this exciting to the want outstanding excited and with hundreds dive Insulet
I our And expansion customers skilled people impact margin while helping also global diabetes. and our Jim, around world leadership to with look and advance the make revenue partnering positive delivering value. a forward talented above on for mission of rest robust growth, with the to all I else, Insulet's our shareholder forward look team to
first our quarter on to Now results.
and we new generated customer starts. First global expectations, quarter strong exceeded our
result growing trends of base, we Omnipod of revenue global retention a utilization driven As remain delivered XX%, global growth our stable. growth and customer and by XX% estimated our
year. point a basis basis to total our first revenue quarter currency XX tailwind a last compared on Foreign was for reported
summer. GX growth was as as bases be growth diabetes X continues pharmacy on X Adoption to by revenue XX%, Omnipod X Omnipod customer type and of channel. the driven volume through U.S. both with robust expect type excited integrated the force, expanding well which market the our half with second we release customer we and this our in new launched driving year, following accelerate planned this are GX, of have market limited starts U.S. full release will to
and for are Our beyond. for business very catalysts sustained U.S. we're growth X revenue robust demand. growth XXXX of revenue and us the success foundation strong, by fueled related laying With and this Omnipod year, ahead many
revenue increased which our Omnipod International XX%, was expectations. above well
increases both the continue Omnipod growth. were X customer overall in to While volume, the and Omnipod accelerated the percentage year's of new our last drive launches largest notable drivers primary DASH remains U.K. of our and Germany international starts in
XXX and and basis primarily prior up year channel premium pods the as performance was XX.X%, almost as due was in manufacturing On improved pharmacy a basis points above which over a in efficiencies. prior The was up reported Gross favorable reported to our tailwind basis, range guide. internal our our with expectations, foreign International XXX year, growth versus basis Delivery the well to currency XXX revenue which on compared was approximately the a $X was guidance point our points Drug gross margin. margin adjusted U.S. which points margins, gross to due million, was revenue basis increase volume exceeded XXX Omnipod timing. on
increased quarter into invest the some expected as in we of multiple our product While year. remainder globally, of operating spend shifted in the launches including timing expenses the business, the
to drive committed continue growth business. efficiencies our well while will as invest remaining global throughout to to above-market as operating gross through in We improvements margin margins expanding
primarily EBITDA and spend. our margin XX.X% revenue, exceeding margin gross as higher-than-expected expectations, revenue adjusted well as and of to was of due Operating XX.X%, timing was both
Turning available ended million approximately under to the cash in million cash quarter and $XXX facility. the and credit liquidity. full our with We $XXX
margins translating increased financial to our anticipated, overall profitable As a into efforts growth stronger drive are expanding profile. and
our Now XXXX to turning outlook.
total XX% growth growth year, a company to XX% total to XX%. the revenue of of range raising range For XX% revenue for a and full to we're expectations Omnipod to
low For range end and expect the our U.S. raising XX% we a of Omnipod, now XX% revenue growth. to are guidance of
adoption, of reoccurring We which our expect growth to the due be provides driven stream benefits to annuity X revenue by Omnipod strong model.
anticipate of second XXXX dollars to half half new XXXX, continue historical levels and seasonality of consistent with in starts first revenue in be customer higher than We both the to the normal trends.
release this the expected of year. of full market acceleration Additionally, of Omnibus to GX to our X the in with the starts half customer planned U.S. contribute summer is new back
We to year growth accelerate further revenue year, expect and are beyond. which starts well positioned we next will this drive new customer
massive market also only X market. the further MDI X as type but penetrate penetration we not We type opportunities from have to continue
We a drivers long are building have our over the product this near excited and accelerated growth portfolio and be to term. X are type one of
expectations a basis we XX% our For International reported XXX of On an now basis, we raising impact by foreign a to Omnipod, to are points. growth revenue basis assume range currency points XX%. unfavorable XXX of
X and growth last to headwinds Omnipod expect the countries offset partially yet X. in We be the not by we Omnipod do U.K. have Germany, year's where driven by launches in
to now U.K. of in half expect XX% the to revenue extent, and rate first and since outlook, we growth revenue from With revenue expected and The launched reflects of second outlook digits. the we and Germany, revised up of substantial expectations. X our international We outperformance in in half year-over-year high growth customer originally also starts first profile, similar the in Omnipod launches prior in to XX% additional year a new the the lesser single half our the be XXXX. growth
XXXX. We XQ growth annuity more recent expect new in nature to the contribute given year in meaningfully revenue of of half X the in our customer to our our the to Omnipod launches contribute to second model and starts
and momentum market Omnipod share launch. in internationally, confident strong drive that we have gain We X which and every are will we growth in
this materially in for ramping International outlook. new revenue to for generations. not prior For we do XXXX. product full launches in the Omnipod inventory and This resulting reducing the fluctuations both launches we year impact expect We expect levels and our U.S. Omnipod, includes from many quarterly have channels
of reaffirming XX% Delivery, Drug we expectations for to Lastly, XX% are decline. our a
XXXX to Turning gross margin.
We XX% reaffirming XX%, the range. are to a midpoint to range closer of of the
product come opportunities facility. of number in want be could risks with expansion a up year, given our have with further we this manufacturing that we gross expectations significant While standing a that to new result and prudent launches margin
near a so. We doing driving continue fantastic term, position expansion we committed gross to margin and are remain in and over further to long the
operating increased an have commitment to also expansion. We drive margin
While operating we to our we drive to to launches, clinical expect continue efficiencies expect R&D, our of and some and scale. as we leverage economies expenses increase we in invest on capitalize as commercial operating now
margin up result, raising original XX.X%, approximately we As a XX are our points to expectations from our operating basis expectations.
Although effective we tax our provide don't to grow. income to our rate, will continues guide I color since
income doubled changes rate our almost first effective to jurisdictions. Our in due among X% tax quarter approximately distribution to
reduction our year annualized our against positive of the in noncash would result is assets the the longer we in period a approximately this deferred purposes. to that for $XXX recorded, rate may We for in Given near valuation we adjust needed. the XX% of tax this trend operational expense conclude we Subsequently, reach income would non-GAAP tax which million rate have term. estimate is effective net earnings, out our release tax no may a point allowance increase the we estimated run an where
guidance. quarter our to Turning XXXX second
We expect to total and of total to Omnipod growth XX% company XX% of growth XX%. XX%
Omnipod, meaningful quarter, for as GX we starts momentum, we partially pod we the second to of begin the our sequential For bringing catalysts we half benefits many of growth continued expect X, and it second expect expect of GX pharmacy sequential starts And we XX% strong offset some taking customer new advantages ongoing With ramp of by annuity channel, to our adoption down customer growth pods. Growth include Omnipod to dollar growth new U.S. model. XX%. in wholesalers inventory the U.S. with the see drivers discussed.
adoption headwinds On not ongoing of we For reported driven in unfavorable expect we do where Omnipod an expect to our XX% by foreign X. a of offset markets, X we points. currency basis, initial International impact Omnipod partially XXX basis countries have the Omnipod, growth in XX%, by of
to with incredibly weeks reflect of expect incredible our successful first are strategy markets. and first ahead, international am accomplish, we had QX my I as been results few joining. the envisioned new $X execution million.
In I Finally, U.S. our which revenue I Delivery impressed Drug continued robust approximately what be more our that In than well lie to strong $X million starts opportunities by before even quarter both have in continues at Insulet, energized to greater company the customer conclusion, and as
to of and remain We are beyond. year the positioned expansion this committed balance well and well for and margin growth sustained delivering revenue
please With call operator, for that, the open questions.
